25-hydroxyvitamin D3 1-alpha-hydroxylase-dependent stimulation of Renal Klotho expression by spironolactone

Kidney and Blood Pressure Research

Volumn 37, Issue 4-5, 2013, Pages 475-487

  Alesutan, Ioana ^a   Feger, Martina ^a   Pakladok, Tatsiana ^a   Mia, Sobuj ^a   Ahmed, Mohamed Siyabeldin E ^a   Voelkl, Jakob ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

25 hydroxyvitamin D3 1 alpha hydroxylase; Aldosterone; CYP27B1; KLOTHO; Mineralocorticoid receptor; Spironolactone; Vitamin D3 receptor

Indexed keywords

ALDOSTERONE; CALCIDIOL 1 MONOOXYGENASE; COLECALCIFEROL RECEPTOR; CYTOCHROME P 450 27B1; CYTOCHROME P450; DEOXYCORTICOSTERONE ACETATE; KLOTHO PROTEIN; MESSENGER RNA; SPIRONOLACTONE; UNCLASSIFIED DRUG; DRINKING WATER; MINERALOCORTICOID RECEPTOR; VITAMIN D RECEPTOR; BETA GLUCURONIDASE;

ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; GENE SILENCING; HEK293 CELL LINE; MALE; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECT; GENE EXPRESSION REGULATION; KIDNEY; METABOLISM; PHYSIOLOGY;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONIDASE; HEK293 CELLS; HUMANS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; SPIRONOLACTONE;

EID: 84890345894     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000355728     Document Type: Article

References (73)

1. Kuro-o M: Klotho. Pflugers Arch 2010;459:333-343
2. Drueke TB: Klotho, FGF23, and FGF receptors in chronic kidney disease: A yin-yang situation? Kidney Int 2010;78:1057-1060
3. Takeshita K, Fujimori T, Kurotaki Y, Honjo H, Tsujikawa H, Yasui K, Lee JK, Kamiya K, Kitaichi K, Yamamoto K, Ito M, Kondo T, Iino S, Inden Y, Hirai M, Murohara T, Kodama I, Nabeshima Y: Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation 2004;109:1776- 1782
4. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y: Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003;17:2393-2403
5. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y: Secreted Klotho protein in sera and CSF: Implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 2004;565:143-147
6. Akimoto T, Yoshizawa H, Watanabe Y, Numata A, Yamazaki T, Takeshima E, Iwazu K, Komada T, Otani N, Morishita Y, Ito C, Shiizaki K, Ando Y, Muto S, Kuro O, Kusano E: Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol 2012;13:155
7. Dermaku-Sopjani M, Sopjani M, Saxena A, Shojaiefard M, Bogatikov E, Alesutan I, Eichenmuller M, Lang F: Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho. Cell Physiol Biochem 2011;28:251-258
8. Kuro-o M: Klotho in health and disease. Curr Opin Nephrol Hypertens 2012;21:362-368
9. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51
10. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro O, Moe OW: Klotho Deficiency Causes Vascular Calcification in Chronic Kidney Disease. J Am Soc Nephrol 2011;22:124-136
11. Ohnishi M, Razzaque MS: Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 2010;24:3562-3571
12. Moreno JA, Izquierdo MC, Sanchez-Nino MD, Suarez-Alvarez B, Lopez-Larrea C, Jakubowski A, Blanco J, Ramirez R, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB: The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB. J Am Soc Nephrol 2011;22:1315-1325
13. Tang C, Pathare G, Michael D, Fajol A, Eichenmuller M, Lang F: Downregulation of Klotho expression by dehydration. Am J Physiol Renal Physiol 2011;301:F745-F750
14. Tang R, Zhou QL, Ao X, Peng WS, Veeraragoo P, Tang TF: Fosinopril and losartan regulate klotho gene and nicotinamide adenine dinucleotide phosphate oxidase expression in kidneys of spontaneously hypertensive rats. Kidney Blood Press Res 2011;34:350-357
15. Yoon HE, Ghee JY, Piao S, Song JH, Han DH, Kim S, Ohashi N, Kobori H, Kuro-o M, Yang CW: Angiotensin II blockade upregulates the expression of Klotho, the anti-Ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 2011;26:800-813
16. Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, Takahashi M, Boothman DA, Kuro-o M: Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011;286:8655-8665
17. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M: Suppression of aging in mice by the hormone Klotho. Science 2005;309:1829-1833
18. Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T, Sasaki T, Fujimori T, Xie P, Kanwar YS: Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci U S A 2007;104:2331-2336
19. Ko GJ, Lee EA, Jeon US, Pyo HJ, Chin HJ, Chae DW, Kim S, Kwon YJ: The Association of Klotho Polymorphism with Disease Progression and Mortality in IgA Nephropathy. Kidney Blood Press Res 2012;36:191-199
20. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL: Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012;125:2243-2255
21. Xie J, Cha SK, An SW, Kuro O, Birnbaumer L, Huang CL: Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun 2012;3:1238
22. Fischer SS, Kempe DS, Leibrock CB, Rexhepaj R, Siraskar B, Boini KM, Ackermann TF, Foller M, Hocher B, Rosenblatt KP, Kuro O, Lang F: Hyperaldosteronism in Klotho-deficient mice. Am J Physiol Renal Physiol 2010;299:F1171-F1177
23. Hadchouel J, Busst C, Procino G, Valenti G, Chambrey R, Eladari D: Regulation of extracellular fluid volume and blood pressure by pendrin. Cell Physiol Biochem 2011;28:505-512
24. Jia EZ, Xu ZX, Guo CY, Li L, Gu Y, Zhu TB, Wang LS, Cao KJ, Ma WZ, Yang ZJ: Renin-Angiotensin-Aldosterone system gene polymorphisms and coronary artery disease: Detection of gene-gene and gene-environment interactions. Cell Physiol Biochem 2012;29:443-452
25. Makowka A, Olejniczak-Fortak M, Nowicki M: A Comparison of the Antihypertensive and Anti- Inflammatory Effects of Aliskiren and Ramipril Add-On Therapy in Peritoneal Dialysis Patients - A Pilot Open Label Study. Kidney Blood Press Res 2012;36:18-25
26. Marney AM, Brown NJ: Aldosterone and end-organ damage. Clin Sci (Lond) 2007;113:267-278
27. McCurley A, Jaffe IZ: Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012;350:256-265
28. Nowakowska FE, Herlitz H, Saeed A, Attman PO, Jensen G, Alaupovic P, Guron G: Lipoprotein abnormalities in patients with atherosclerotic renovascular disease. Kidney Blood Press Res 2011;34:311-319
29. Jain G, Campbell RC, Warnock DG: Mineralocorticoid receptor blockers and chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1685-1691
30. Voelkl J, Alesutan I, Leibrock CB, Quintanilla-Martinez L, Kuhn V, Feger M, Mia S, Ahmed MS, Rosenblatt KP, Kuro O, Lang F: Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klothohypomorphic mice. J Clin Invest 2013;123:812-822
31. Wu SY, Yu YR, Cai Y, Jia LX, Wang X, Xiao CS, Tang CS, Qi YF: Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood) 2012;237:31-37
32. Guney I, Selcuk NY, Altintepe L, Atalay H, Basarali MK, Buyukbas S: Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Ren Fail 2009;31:779-784
33. Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982;21:98-101
34. Jaffe IZ, Mendelsohn ME: Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005;96:643-650
35. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME: Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol 2007;27:799-805
36. Kiyosue A, Nagata D, Myojo M, Sato T, Takahashi M, Satonaka H, Nagai R, Hirata Y: Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element. Hypertens Res 2011;34:1283-1287
37. Boini KM, Hennige AM, Huang DY, Friedrich B, Palmada M, Boehmer C, Grahammer F, Artunc F, Ullrich S, Avram D, Osswald H, Wulff P, Kuhl D, Vallon V, Haring HU, Lang F: Serum- And glucocorticoid-inducible kinase 1 mediates salt sensitivity of glucose tolerance. Diabetes 2006;55:2059-2066
38. Mulatero P, Milan A, Williams TA, Veglio F: Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem 2006;4:75-91
39. Epstein M, Calhoun DA: Aldosterone blockers (mineralocorticoid receptor antagonism) and potassiumsparing diuretics. J Clin Hypertens (Greenwich) 2011;13:644-648
40. Lammers C, Dartsch T, Brandt MC, Rottlander D, Halbach M, Peinkofer G, Ockenpoehler S, Weiergraeber M, Schneider T, Reuter H, Muller-Ehmsen J, Hescheler J, Hoppe UC, Zobel C: Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat. Cell Physiol Biochem 2012;29:833-840
41. Azuma M, Koyama D, Kikuchi J, Yoshizawa H, Thasinas D, Shiizaki K, Kuro-o M, Furukawa Y, Kusano E: Promoter methylation confers kidney-specific expression of the Klotho gene. FASEB J 2012;26:4264-4274
42. Zhang H, Li Y, Fan Y, Wu J, Zhao B, Guan Y, Chien S, Wang N: Klotho is a target gene of PPAR-gamma. Kidney Int 2008;74:732-739
43. Messa P, Alfieri C, Rastaldi MP: Recent insights into vitamin D and its receptor. J Nephrol 2011;24:S30-S37
44. Haussler MR, Haussler CA, Whitfield GK, Hsieh JC, Thompson PD, Barthel TK, Bartik L, Egan JB, Wu Y, Kubicek JL, Lowmiller CL, Moffet EW, Forster RE, Jurutka PW: The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging. J Steroid Biochem Mol Biol 2010;121:88-97
45. Yoshida T, Fujimori T, Nabeshima Y: Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology 2002;143:683-689
46. Razzaque MS, Sitara D, Taguchi T, St Arnaud R, Lanske B: Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 2006;20:720-722
47. Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, Gekle M: Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 2005;19:1697-1710
48. Hansen PR, Rieneck K, Bendtzen K: Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett 2004;91:87-91
49. Schuetz EG, Brimer C, Schuetz JD: Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol Pharmacol 1998;54:1113-1117
50. Sonder SU, Mikkelsen M, Rieneck K, Hedegaard CJ, Bendtzen K: Effects of spironolactone on human blood mononuclear cells: Mineralocorticoid receptor independent effects on gene expression and late apoptosis induction. Br J Pharmacol 2006;148:46-53
51. Sonder SU, Woetmann A, Odum N, Bendtzen K: Spironolactone induces apoptosis and inhibits NF-kappaB independent of the mineralocorticoid receptor. Apoptosis 2006;11:2159-2165
52. Fukuda S, Horimai C, Harada K, Wakamatsu T, Fukasawa H, Muto S, Itai A, Hayashi M: Aldosterone-induced kidney injury is mediated by NFkappaB activation. Clin Exp Nephrol 2011;15:41-49
53. Ebert R, Jovanovic M, Ulmer M, Schneider D, Meissner-Weigl J, Adamski J, Jakob F: Down-regulation by nuclear factor kappaB of human 25-hydroxyvitamin D3 1alpha-hydroxylase promoter. Mol Endocrinol 2004;18:2440-2450
54. Pilz S, Tomaschitz A, Friedl C, Amrein K, Drechsler C, Ritz E, Boehm BO, Grammer TB, Marz W: Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant 2011;26:3603-3609
55. Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, Inoue M, Fujimoto S, Ikebe M, Yuasa K, Yamanaka S, Sugiura T, Terada Y: Serum levels of soluble secreted alpha-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol 2012;16:722-729
56. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM: Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate. Circ Res 2011;109:697-711
57. Becker LE, Koleganova N, Piecha G, Noronha IL, Zeier M, Geldyyev A, Kokeny G, Ritz E, Gross ML: Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am J Physiol Renal Physiol 2011;300:F772-F782
58. Guerrero F, Montes de Oca A, Aguilera-Tejero E, Zafra R, Rodriguez M, Lopez I: The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transplant 2012;27:2206- 2212
59. Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro O, Moe OW, Giachelli CM: Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012;82:1261-1270
60. Molinari C, Uberti F, Grossini E, Vacca G, Carda S, Invernizzi M, Cisari C: 1alpha,25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells. Cell Physiol Biochem 2011;27:661-668
61. Guessous I, Bochud M, Bonny O, Burnier M: Calcium, vitamin D and cardiovascular disease. Kidney Blood Press Res 2011;34:404-417
62. Vedralova M, Kotrbova-Kozak A, Zeleznikova V, Zoubkova H, Rychlik I, Cerna M: Polymorphisms in the Vitamin D Receptor Gene and Parathyroid Hormone Gene in the Development and Progression of Diabetes Mellitus and its Chronic Complications, Diabetic Nephropathy and Non-Diabetic Renal Disease. Kidney Blood Press Res 2012;36:1-9
63. Ikushima M, Rakugi H, Ishikawa K, Maekawa Y, Yamamoto K, Ohta J, Chihara Y, Kida I, Ogihara T: Antiapoptotic and anti-senescence effects of Klotho on vascular endothelial cells. Biochem Biophys Res Commun 2006;339:827-832
64. Kusaba T, Okigaki M, Matui A, Murakami M, Ishikawa K, Kimura T, Sonomura K, Adachi Y, Shibuya M, Shirayama T, Tanda S, Hatta T, Sasaki S, Mori Y, Matsubara H: Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci U S A 2010;107:19308-19313
65. Satoh M, Nagasu H, Morita Y, Yamaguchi TP, Kanwar YS, Kashihara N: Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling. Am J Physiol Renal Physiol 2012;303:F1641-F1651
66. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N: Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis. Arterioscler Thromb Vasc Biol 201333:67-75
67. Barrera-Chimal J, Perez-Villalva R, Rodriguez-Romo R, Reyna J, Uribe N, Gamba G, Bobadilla NA: Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 2013;83:93-103
68. Quaschning T, Ruschitzka F, Shaw S, Luscher TF: Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001;37:801-805
69. Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS: Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 2004;172:1590-1594
70. Ritz E, Koleganova N: Aldosterone in uremia - beyond blood pressure. Blood Purif 2010;29:111-113
71. Bianchi S, Bigazzi R, Campese VM: Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis 2005;46:45-51
72. Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN: The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012;73:447- 454
73. Heshka J, Ruzicka M, Hiremath S, McCormick BB: Spironolactone for difficult to control hypertension in chronic kidney disease: An analysis of safety and efficacy. J Am Soc Hypertens 2010;4:295-301